mitoxantrone has been researched along with Cancer, Second Primary in 42 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The incidence of secondary myelodysplasia/acute myeloid leukemia (AML) was retrospectively assessed in an international joint study in 305 node-positive breast cancer patients, who received mitoxantrone-based high-dose chemotherapy (HDCT) followed by autologous stem cell support as adjuvant therapy." | 8.82 | Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients. ( Damon, L; Demirer, T; Derigs, G; Ferrante, P; Kröger, N; Rosti, G; Wandt, H; Zander, AR, 2003) |
| "Two cases of therapy-related acute leukemia (TRAL) after the use of Mitoxantrone for the treatment of secondary progressive multiple sclerosis (MS) are reported." | 7.78 | Therapy-related acute leukemia in two patients with multiple sclerosis treated with Mitoxantrone. ( Colovic, N; Dencic Fekete, M; Djordjevic, V; Drulovic, J; Kraguljac Kurtovic, N; Suvajdzic, N; Tomin, D; Vidovic, A, 2012) |
| "Therapy-related acute promyelocytic leukemia (t-APL) with t(15;17)(q22;q21) involving the PML and RARA genes is associated with exposure to agents targeting topoisomerase II (topoII), particularly mitoxantrone and epirubicin." | 7.76 | Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia. ( Byl, JA; Chang, C; Corser, R; Felix, CA; Grimwade, D; Hasan, SK; Hoyle, C; Lo-Coco, F; Mays, AN; Osheroff, N; Parker, AN; Peniket, A; Saravanamuttu, K; Solomon, E; Wiemels, JL; Xiao, Y, 2010) |
| " We observed 10 cases of such t-AML over a 7-year-period in breast cancer patients treated with mitoxantrone combined with fluorouracil, cyclophosphamide and regional radiotherapy, and in three cases with vindesine." | 7.70 | Early secondary acute myelogenous leukemia in breast cancer patients after treatment with mitoxantrone, cyclophosphamide, fluorouracil and radiation therapy. ( Barin, C; Benboubker, L; Binet, C; Brémond, JL; Calais, G; Cartron, G; Colombat, P; Delain, M; Georget, MT; Lamagnère, JP; Leloup, R; Letortorec, S; Linassier, C; Petit, A; Raban, N, 2000) |
| "Fludarabine is an effective treatment for follicular lymphoma (FL), but exposure to it negatively impacts stem cell mobilization and may increase the risk of subsequent myelodysplastic syndrome and acute myelogenous leukemia (t-MDS/AML)." | 5.16 | Fludarabine as a risk factor for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation. ( Andresen, S; Bolwell, B; Copelan, E; Dean, R; Kalaycio, M; Pohlman, B; Rybicki, L; Sobecks, R; Sweetenham, J; Waterman, J, 2012) |
| "Concomitant radiotherapy with adjuvant fluorouracil, mitoxantrone, and cyclophosphamide has significantly better locoregional control in node-positive breast cancer after conservative surgery and 50% shorter treatment, albeit with slightly more acute toxicity." | 5.12 | A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: final results. ( Bertheault-Cvitkovic, F; Castèra, D; Combe, M; de la Lande, B; Demange, L; Garbay, JR; Graïc, Y; Krzisch, C; Leduc, B; Lucas, V; Mouret-Fourme, E; Nguyen, TD; Noguès, C; Rouëssé, J; Serin, D; Villet, R, 2006) |
| "The objective of the current study was to assess the efficacy of combination therapy with fludarabine and mitoxantrone in patients with B-cell chronic lymphocytic leukemia (CLL)." | 5.11 | Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia. ( Andreeff, M; Beran, M; Ferrajoli, A; Giles, FJ; Kantarjian, HM; Keating, MJ; Lerner, S; O'Brien, S; Tsimberidou, AM; Wierda, WG, 2004) |
| "The incidence of secondary myelodysplasia/acute myeloid leukemia (AML) was retrospectively assessed in an international joint study in 305 node-positive breast cancer patients, who received mitoxantrone-based high-dose chemotherapy (HDCT) followed by autologous stem cell support as adjuvant therapy." | 4.82 | Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients. ( Damon, L; Demirer, T; Derigs, G; Ferrante, P; Kröger, N; Rosti, G; Wandt, H; Zander, AR, 2003) |
| "Two cases of therapy-related acute leukemia (TRAL) after the use of Mitoxantrone for the treatment of secondary progressive multiple sclerosis (MS) are reported." | 3.78 | Therapy-related acute leukemia in two patients with multiple sclerosis treated with Mitoxantrone. ( Colovic, N; Dencic Fekete, M; Djordjevic, V; Drulovic, J; Kraguljac Kurtovic, N; Suvajdzic, N; Tomin, D; Vidovic, A, 2012) |
| "Therapy-related acute promyelocytic leukemia (t-APL) with t(15;17)(q22;q21) involving the PML and RARA genes is associated with exposure to agents targeting topoisomerase II (topoII), particularly mitoxantrone and epirubicin." | 3.76 | Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia. ( Byl, JA; Chang, C; Corser, R; Felix, CA; Grimwade, D; Hasan, SK; Hoyle, C; Lo-Coco, F; Mays, AN; Osheroff, N; Parker, AN; Peniket, A; Saravanamuttu, K; Solomon, E; Wiemels, JL; Xiao, Y, 2010) |
| "Drug-induced cleavage of DNA by topoisomerase II mediates the formation of chromosomal translocation breakpoints in mitoxantrone-related APL and in APL that occurs after therapy with other topoisomerase II poisons." | 3.73 | DNA topoisomerase II in therapy-related acute promyelocytic leukemia. ( Adès, L; Blair, IA; Cassinat, B; Chomienne, C; Cross, NC; Felix, CA; Fenaux, P; Grimwade, D; Lafage-Pochitaloff, M; Mason, A; Mistry, AR; Osheroff, N; Parry, A; Peniket, AJ; Reiter, A; Segal, MR; Solomon, E; Walz, C; Whitmarsh, RJ; Wiemels, JL, 2005) |
| "We report the development of therapy-related early pre-B acute lymphoblastic leukemia in a patient administered a topoisomerase II inhibitor, etoposide, a consolidation therapy agent for acute promyelocytic leukemia." | 3.72 | MLL/AF-1p fusion in therapy-related early pre-B acute lymphoblastic leukemia with t(1;11)(p32;q23) translocation developing in the relapse phase of acute promyelocytic leukemia. ( Kondo, T; Mikami, M; Nakanishi, H; Otsuki, T; Suemori, S; Suetsugu, Y; Sugihara, T; Tsujioka, T; Wada, H; Yamamori, S, 2003) |
| " We report the case history of a patient with myelodyspasia occurring after neoadjuvant methotrexate, mitoxantrone and mitomycin C (triple M) chemotherapy with subsequent radiotherapy for locally advanced breast cancer." | 3.70 | Myelodysplastic syndrome as a complication of neo-adjuvant triple M chemotherapy and radiotherapy. ( Lowdell, CP; Partridge, SE, 1999) |
| "Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2." | 3.70 | Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma. ( Ashley, S; Kuan, A; Kulkarni, S; Mehta, J; Mitchell, P; Powles, R; Powles, T; Saso, R; Swansbury, GJ; Treleaven, J, 2000) |
| "The combination of adjuvant radiotherapy and chemotherapy with mitoxantrone induces a high risk of acute leukemia in patients with breast cancer." | 3.70 | Increased risk of acute leukemia after adjuvant chemotherapy for breast cancer: a population-based study. ( Bonithon-Kopp, C; Carli, PM; Chaplain, G; Milan, C; Sgro, C, 2000) |
| " We observed 10 cases of such t-AML over a 7-year-period in breast cancer patients treated with mitoxantrone combined with fluorouracil, cyclophosphamide and regional radiotherapy, and in three cases with vindesine." | 3.70 | Early secondary acute myelogenous leukemia in breast cancer patients after treatment with mitoxantrone, cyclophosphamide, fluorouracil and radiation therapy. ( Barin, C; Benboubker, L; Binet, C; Brémond, JL; Calais, G; Cartron, G; Colombat, P; Delain, M; Georget, MT; Lamagnère, JP; Leloup, R; Letortorec, S; Linassier, C; Petit, A; Raban, N, 2000) |
| "The most effective regimen for relapsed acute myeloid leukemia (AML) patients who do not achieve complete remission (CR) after a course of salvage therapy has not been established." | 2.77 | Fludarabine and cytarabine in patients with relapsed acute myeloid leukemia refractory to initial salvage therapy. ( Agha, M; Boyiadzis, M; Duggal, S; Hou, JZ; Im, A; Lin, Y; McLaughlin, B; Raptis, A; Redner, R; Smith, C, 2012) |
| "Cytoreduction with 4 courses of R-FM was safe and highly efficient in patients with recurrent/refractory follicular lymphoma who had high tumor burden; however, better consolidation than FM is needed to further improve outcome." | 2.75 | Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adult ( Brice, P; Copin, MC; Fermé, C; Feugier, P; Lamy, T; Morschhauser, F; Mounier, N; Sebban, C; Solal-Celigny, P; Tilly, H, 2010) |
| "Treatment of acute promyelocytic leukemia (APL) with a combination of anthracycline-based chemotherapy and all-trans retinoic acid (ATRA) leads to very high rates of complete remission and survival." | 1.35 | Translocation (2;11)(q37;q23) in therapy-related myelodysplastic syndrome after treatment for acute promyelocytic leukemia. ( Mellink, CH; Snijder, S; van der Lelie, H, 2008) |
| "Nine non-breast cancers were observed versus 2." | 1.30 | Cancer risk after adjuvant chemo- or chemohormonal therapy of breast cancer. ( Hirvikoski, PP; Johansson, RT; Kumpulainen, EJ; Pukkala, E, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (23.81) | 18.2507 |
| 2000's | 19 (45.24) | 29.6817 |
| 2010's | 13 (30.95) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boddu, PC | 1 |
| Zeidan, AM | 1 |
| Robak, T | 1 |
| Blonski, JZ | 1 |
| Gora-Tybor, J | 1 |
| Calbecka, M | 1 |
| Dwilewicz-Trojaczek, J | 1 |
| Boguradzki, P | 1 |
| Dmoszynska, A | 1 |
| Kowal, M | 1 |
| Kloczko, J | 1 |
| Piszcz, J | 1 |
| Stella-Holowiecka, B | 1 |
| Sulek, K | 1 |
| Kuliczkowski, K | 1 |
| Potoczek, S | 1 |
| Warzocha, K | 1 |
| Lech-Maranda, E | 1 |
| Skotnicki, AB | 1 |
| Piotrowska, M | 1 |
| Moskwa, A | 1 |
| Zawilska, K | 1 |
| Jamroziak, K | 1 |
| Ottone, T | 1 |
| Hasan, SK | 2 |
| Voso, MT | 1 |
| Ledda, A | 1 |
| Montefusco, E | 1 |
| Fenu, S | 1 |
| Pagoni, M | 1 |
| Hubmann, M | 1 |
| Lunghi, M | 1 |
| Platzbecker, U | 1 |
| Lo-Coco, F | 2 |
| Jang, W | 1 |
| Kim, M | 1 |
| Lee, JW | 1 |
| Chung, NG | 1 |
| Tang, YL | 1 |
| Chia, WK | 1 |
| Yap, EC | 1 |
| Julia, MI | 1 |
| Leong, CF | 1 |
| Salwati, S | 1 |
| Wong, CL | 1 |
| Betancourt-García, RD | 1 |
| Castro, J | 1 |
| Fernández, AC | 1 |
| López-Enríquez, A | 1 |
| Fradera, J | 1 |
| Pacheco, E | 1 |
| Mays, AN | 1 |
| Osheroff, N | 2 |
| Xiao, Y | 1 |
| Wiemels, JL | 2 |
| Felix, CA | 2 |
| Byl, JA | 1 |
| Saravanamuttu, K | 1 |
| Peniket, A | 1 |
| Corser, R | 1 |
| Chang, C | 1 |
| Hoyle, C | 1 |
| Parker, AN | 1 |
| Solomon, E | 2 |
| Grimwade, D | 2 |
| Godley, LA | 2 |
| Njiaju, UO | 1 |
| Green, M | 2 |
| Weiner, H | 2 |
| Lin, S | 1 |
| Odenike, O | 2 |
| Rich, ES | 1 |
| Artz, A | 2 |
| Van Besien, K | 2 |
| Daugherty, CK | 1 |
| Zhang, Y | 2 |
| Le Beau, MM | 1 |
| Stock, W | 2 |
| Larson, RA | 2 |
| Morschhauser, F | 1 |
| Mounier, N | 1 |
| Sebban, C | 1 |
| Brice, P | 1 |
| Solal-Celigny, P | 1 |
| Tilly, H | 1 |
| Feugier, P | 1 |
| Fermé, C | 1 |
| Copin, MC | 1 |
| Lamy, T | 1 |
| Waterman, J | 1 |
| Rybicki, L | 1 |
| Bolwell, B | 1 |
| Copelan, E | 1 |
| Pohlman, B | 1 |
| Sweetenham, J | 1 |
| Dean, R | 1 |
| Sobecks, R | 1 |
| Andresen, S | 1 |
| Kalaycio, M | 1 |
| Larson, SM | 1 |
| Campbell, NP | 1 |
| Huo, D | 1 |
| Gajria, D | 1 |
| Daugherty, C | 1 |
| Hyjek, E | 1 |
| Gurbuxani, S | 1 |
| Thirman, M | 1 |
| Sipkins, D | 1 |
| Colovic, N | 1 |
| Suvajdzic, N | 1 |
| Kraguljac Kurtovic, N | 1 |
| Djordjevic, V | 1 |
| Dencic Fekete, M | 1 |
| Drulovic, J | 1 |
| Vidovic, A | 1 |
| Tomin, D | 1 |
| Cowell, IG | 1 |
| Austin, CA | 1 |
| McLaughlin, B | 1 |
| Im, A | 1 |
| Raptis, A | 1 |
| Agha, M | 1 |
| Hou, JZ | 1 |
| Redner, R | 1 |
| Duggal, S | 1 |
| Lin, Y | 1 |
| Smith, C | 1 |
| Boyiadzis, M | 1 |
| Kröger, N | 1 |
| Damon, L | 1 |
| Zander, AR | 1 |
| Wandt, H | 1 |
| Derigs, G | 1 |
| Ferrante, P | 1 |
| Demirer, T | 1 |
| Rosti, G | 1 |
| Tsujioka, T | 1 |
| Wada, H | 1 |
| Yamamori, S | 1 |
| Otsuki, T | 1 |
| Suemori, S | 1 |
| Kondo, T | 1 |
| Nakanishi, H | 1 |
| Suetsugu, Y | 1 |
| Mikami, M | 1 |
| Sugihara, T | 1 |
| Chronowski, GM | 1 |
| Wilder, RB | 1 |
| Levy, LB | 1 |
| Atkinson, EN | 1 |
| Ha, CS | 1 |
| Hagemeister, FB | 1 |
| Barista, I | 1 |
| Rodriguez, MA | 1 |
| Sarris, AH | 1 |
| Hess, MA | 1 |
| Cabanillas, F | 1 |
| Cox, JD | 1 |
| Tsimberidou, AM | 1 |
| Keating, MJ | 1 |
| Giles, FJ | 1 |
| Wierda, WG | 1 |
| Ferrajoli, A | 1 |
| Lerner, S | 1 |
| Beran, M | 1 |
| Andreeff, M | 2 |
| Kantarjian, HM | 1 |
| O'Brien, S | 1 |
| Hendry, L | 1 |
| Bowen, A | 1 |
| Matutes, E | 1 |
| Swansbury, J | 1 |
| Catovsky, D | 1 |
| Mistry, AR | 1 |
| Whitmarsh, RJ | 1 |
| Mason, A | 1 |
| Reiter, A | 1 |
| Cassinat, B | 1 |
| Parry, A | 1 |
| Walz, C | 1 |
| Segal, MR | 1 |
| Adès, L | 1 |
| Blair, IA | 1 |
| Peniket, AJ | 1 |
| Lafage-Pochitaloff, M | 1 |
| Cross, NC | 1 |
| Chomienne, C | 1 |
| Fenaux, P | 1 |
| Rouëssé, J | 1 |
| de la Lande, B | 1 |
| Bertheault-Cvitkovic, F | 1 |
| Serin, D | 1 |
| Graïc, Y | 1 |
| Combe, M | 1 |
| Leduc, B | 1 |
| Lucas, V | 1 |
| Demange, L | 1 |
| Nguyen, TD | 1 |
| Castèra, D | 1 |
| Krzisch, C | 1 |
| Villet, R | 1 |
| Mouret-Fourme, E | 1 |
| Garbay, JR | 1 |
| Noguès, C | 1 |
| Au, WY | 1 |
| Chan, LC | 1 |
| Liang, R | 1 |
| Kwong, YL | 1 |
| Snijder, S | 1 |
| Mellink, CH | 1 |
| van der Lelie, H | 1 |
| Roulston, D | 1 |
| Anastasi, J | 1 |
| Rudinsky, R | 1 |
| Nucifora, G | 1 |
| Zeleznik-Le, N | 1 |
| Rowley, JD | 1 |
| McGavran, L | 1 |
| Tsuchida, M | 1 |
| Hayashi, Y | 1 |
| Todisco, E | 1 |
| Testi, AM | 1 |
| Avvisati, G | 1 |
| Moleti, ML | 1 |
| Cedrone, M | 1 |
| Cimino, G | 1 |
| Mancini, F | 1 |
| Amadori, S | 1 |
| Mandelli, F | 1 |
| Philpott, NJ | 1 |
| Bevan, DH | 1 |
| Gordon-Smith, EC | 1 |
| List, AF | 1 |
| Spier, CS | 1 |
| Grogan, TM | 1 |
| Johnson, C | 1 |
| Roe, DJ | 1 |
| Greer, JP | 1 |
| Wolff, SN | 1 |
| Broxterman, HJ | 1 |
| Scheffer, GL | 1 |
| Scheper, RJ | 1 |
| Dalton, WS | 1 |
| Izumi, T | 1 |
| Ohtsuki, T | 1 |
| Ohya, K | 1 |
| Ogawa, Y | 1 |
| Yoshida, M | 1 |
| Muroi, K | 1 |
| Imagawa, S | 1 |
| Hatake, K | 1 |
| Kuriki, K | 1 |
| Saito, K | 1 |
| Miura, Y | 1 |
| Melillo, LM | 1 |
| Sajeva, MR | 1 |
| Musto, P | 1 |
| Perla, G | 1 |
| Cascavilla, N | 1 |
| Minervini, MM | 1 |
| D'Arena, G | 1 |
| Carotenuto, M | 1 |
| Kumpulainen, EJ | 1 |
| Hirvikoski, PP | 1 |
| Pukkala, E | 1 |
| Johansson, RT | 1 |
| Orlandi, E | 1 |
| Lazzarino, M | 1 |
| Bernasconi, P | 1 |
| Astori, C | 1 |
| Bernasconi, C | 1 |
| Lemoli, RM | 1 |
| Visani, G | 1 |
| Leopardi, G | 1 |
| Motta, MR | 1 |
| Rizzi, S | 1 |
| Testoni, N | 1 |
| Curti, A | 1 |
| Tura, S | 1 |
| Partridge, SE | 1 |
| Lowdell, CP | 1 |
| Saso, R | 1 |
| Kulkarni, S | 1 |
| Mitchell, P | 1 |
| Treleaven, J | 1 |
| Swansbury, GJ | 1 |
| Mehta, J | 1 |
| Powles, R | 1 |
| Ashley, S | 1 |
| Kuan, A | 1 |
| Powles, T | 1 |
| Chaplain, G | 1 |
| Milan, C | 1 |
| Sgro, C | 1 |
| Carli, PM | 1 |
| Bonithon-Kopp, C | 1 |
| Hossfeld, DK | 1 |
| Linassier, C | 1 |
| Barin, C | 1 |
| Calais, G | 1 |
| Letortorec, S | 1 |
| Brémond, JL | 1 |
| Delain, M | 1 |
| Petit, A | 1 |
| Georget, MT | 1 |
| Cartron, G | 1 |
| Raban, N | 1 |
| Benboubker, L | 1 |
| Leloup, R | 1 |
| Binet, C | 1 |
| Lamagnère, JP | 1 |
| Colombat, P | 1 |
| Ghalie, RG | 1 |
| Goodkin, DE | 1 |
| Seiter, K | 1 |
| Feldman, EJ | 1 |
| Sreekantaiah, C | 1 |
| Pozzuoli, M | 1 |
| Weisberger, J | 1 |
| Liu, D | 1 |
| Papageorgio, C | 1 |
| Weiss, M | 1 |
| Kancherla, R | 1 |
| Ahmed, T | 1 |
| Kimby, E | 1 |
| Nygren, P | 1 |
| Glimelius, B | 1 |
| Wulf, GG | 1 |
| Wang, RY | 1 |
| Kuehnle, I | 1 |
| Weidner, D | 1 |
| Marini, F | 1 |
| Brenner, MK | 1 |
| Goodell, MA | 1 |
| Hambach, L | 1 |
| Eder, M | 1 |
| Dammann, E | 1 |
| Battmer, K | 1 |
| Stucki, A | 1 |
| Heil, G | 1 |
| Ganser, A | 1 |
| Hertenstein, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35)[NCT00779883] | Phase 1 | 9 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| A Phase 1B Extension Trial to Allow Repeat Dosing of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35) in Subjects Previously Treated in MDACC Protocol 2004-0914[NCT00783588] | Phase 1 | 4 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| Chemical Exposures and Leukemia Risks and Childhood Leukemia and Environmental Exposure[NCT00015587] | 3,523 participants (Actual) | Observational | 1995-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for mitoxantrone and Cancer, Second Primary
| Article | Year |
|---|---|
Myeloid disorders after autoimmune disease.
Topics: Arthritis, Rheumatoid; Cyclophosphamide; Genetic Predisposition to Disease; Humans; Immunosuppressiv | 2019 |
Acquired acute myelogenous leukemia after therapy for acute promyelocytic leukemia with t(15;17): a case report and review of the literature.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chromosome | 2009 |
Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantat | 2003 |
Therapy-related acute leukemia associated with t(11q23) after primary acute myeloid leukemia with t(8;21): a report of two cases.
Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents, Phytogenic; Antineoplastic Combine | 1995 |
Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chrom | 2001 |
A systematic overview of chemotherapy effects in acute myeloid leukaemia.
Topics: Acute Disease; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow | 2001 |
Donor cell-derived acute myeloid leukemia developing 14 months after matched unrelated bone marrow transplantation for chronic myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Bone Marrow Transplantation | 2001 |
8 trials available for mitoxantrone and Cancer, Second Primary
| Article | Year |
|---|---|
Long-term results of the Polish Adult Leukemia Group PALG-CLL2 phase III randomized study comparing cladribine-based combinations in chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cladribine; Cyclophosphamide; Humans | 2014 |
Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 2010 |
Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adult
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2010 |
Fludarabine as a risk factor for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation.
Topics: Adult; Antineoplastic Agents; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell | 2012 |
Fludarabine and cytarabine in patients with relapsed acute myeloid leukemia refractory to initial salvage therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; | 2012 |
Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Follow-Up | 2004 |
Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration S | 2004 |
Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration S | 2004 |
Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration S | 2004 |
Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration S | 2004 |
A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: final results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2006 |
27 other studies available for mitoxantrone and Cancer, Second Primary
| Article | Year |
|---|---|
Genomic analysis of therapy-related acute promyelocytic leukemias arising after malignant and non-malignant disorders.
Topics: Adult; Aged; Antineoplastic Agents; Chromosome Breakpoints; Chromosomes, Human, Pair 15; Chromosomes | 2014 |
Acute myeloid leukemia of mixed megakaryocytic and erythroid origin following chemotherapy for T-cell lymphoblastic lymphoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cytarabine; Daunorubicin; | 2014 |
Dismal outcome of therapy-related myeloid neoplasm associated with complex aberrant karyotypes and monosomal karyotype: a case report.
Topics: Abnormal Karyotype; Antineoplastic Combined Chemotherapy Protocols; Humans; Idarubicin; In Situ Hybr | 2016 |
Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia.
Topics: Adult; Antibiotics, Antineoplastic; Breast Neoplasms; Chromosomes, Human, Pair 15; Chromosomes, Huma | 2010 |
High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML).
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chrom | 2012 |
Therapy-related acute leukemia in two patients with multiple sclerosis treated with Mitoxantrone.
Topics: Acute Disease; Adult; Female; Humans; Leukemia; Male; Middle Aged; Mitoxantrone; Multiple Sclerosis, | 2012 |
Do transcription factories and TOP2B provide a recipe for chromosome translocations in therapy-related leukemia?
Topics: Anthracyclines; DNA Breaks, Double-Stranded; DNA Topoisomerases, Type II; DNA-Binding Proteins; Epir | 2012 |
MLL/AF-1p fusion in therapy-related early pre-B acute lymphoblastic leukemia with t(1;11)(p32;q23) translocation developing in the relapse phase of acute promyelocytic leukemia.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Huma | 2003 |
Second malignancies after chemotherapy and radiotherapy for Hodgkin disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combin | 2004 |
DNA topoisomerase II in therapy-related acute promyelocytic leukemia.
Topics: Antineoplastic Agents; DNA Damage; DNA Repair; DNA Topoisomerases, Type II; DNA, Neoplasm; Doxorubic | 2005 |
Myelodysplastic syndrome and acute myeloid leukemia after treatment with fludarabine, mitoxantrone, and dexamethasone.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans | 2006 |
Translocation (2;11)(q37;q23) in therapy-related myelodysplastic syndrome after treatment for acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cells, Cultured; Chromosomes, Human, Pair 11; Chromo | 2008 |
Therapy-related acute myelomonocytic leukemia following successful treatment for acute promyelocytic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 10; Chromosomes | 1995 |
Secondary leukaemia after MMM combined modality therapy for breast carcinoma.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; F | 1993 |
Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antigens, CD34; Antigens, CD7; Antineopla | 1996 |
Therapy-related leukemia with a novel 21q22 rearrangement.
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chromosomes, Human, Pair 21; | 1996 |
Acute myeloid leukemia following 3M (mitoxantrone, mitomycin and methotrexate) chemotherapy for advanced breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Leukemia, M | 1997 |
Cancer risk after adjuvant chemo- or chemohormonal therapy of breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 1998 |
Secondary acute myeloid leukemia following treatment with VP16-containing regimens for non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleo | 1998 |
Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Bone Marrow Purging; Busulfan; Combined Mod | 1999 |
Myelodysplastic syndrome as a complication of neo-adjuvant triple M chemotherapy and radiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Methotrexate; Midd | 1999 |
Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 2000 |
Increased risk of acute leukemia after adjuvant chemotherapy for breast cancer: a population-based study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Coh | 2000 |
Mitoxantrone-related acute myelocytic leukemias.
Topics: Antineoplastic Agents; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Neoplasms, Second Primary | 2000 |
Early secondary acute myelogenous leukemia in breast cancer patients after treatment with mitoxantrone, cyclophosphamide, fluorouracil and radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The | 2000 |
Secondary leukemia after adjuvant chemotherapy for breast cancer.
Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Humans; Mitoxantrone; Neoplasms, Second Primary; Research | 2001 |
A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antibiotics, Antineoplastic; Ant | 2001 |